Press "Enter" to skip to content

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer – Yahoo Finance

admin 0

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer  Yahoo Finance

Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer.

“liver cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *